Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 511 to 520 of 999 total matches.
Conductive Keratoplasty (CK) for Presbyopia
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004 (Issue 1185)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Methamphetamine Abuse
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Methamphetamine, a highly addictive synthetic sympathomimetic, has again become important as a drug of abuse in the US. Its resurgence has been associated with unsafe sexual practices that have resulted in an increase in HIV transmission, particularly among men who have sex with men (SJ Semple et al, J Subst Abuse Treat 2002; 22:149; A Urbina and K Jones, Clin Infect Dis 2004; 38:890).
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
COX-2 Alternatives and GI Protection
The Medical Letter on Drugs and Therapeutics • Nov 08, 2004 (Issue 1195)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin.
Acetylcysteine (Acetadote) for Acetaminophen Overdosage
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Acetaminophen (paracetamol; Tylenol, and others) taken in overdosage can cause severe hepatic injury and death. Acetaminophen poisoning is treated with (N-)acetylcysteine. Available for many years in the US as a solution for inhalation therapy (Mucomyst, and others), it subsequently became available for oral use and was recently marketed in the US for intravenous (IV) use as Acetadote (Cumberland).
InstaRead Lithium System
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005 (Issue 1219)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
The InstaRead Lithium System (ReliaLAB), an office test that only requires a finger stick to measure lithium serum concentrations, has been cleared by the FDA and is now available. Standard methods for measuring lithium serum concentrations require venipuncture and transport of the specimen to commercial laboratories.
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006 (Issue 1228)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Nelarabine (Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.
Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women
The Medical Letter on Drugs and Therapeutics • May 08, 2006 (Issue 1234)
R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York University School ...
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and others) for prevention of breast cancer in high-risk postmenopausal women.
Mumps Outbreak Recommendations
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006 (Issue 1236)
R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York University School ...
A large mumps outbreak that began in Iowa in December 2005 has spread. About 40% of the cases have been in people 18-25 years old, many of whom are college students and had been vaccinated against the disease.
Finasteride for Prevention of Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride (Proscar, and others) to prevent prostate cancer.